




① J7193	Factor ix (antihemophilic factor, purified, non-recombinant) per i.u. <i>AlphaNine SD, Mononine</i>	K K2	② J7295	Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each <i>Medicare Statute 1862(a)(1)</i> <i>AHA: 4Q 2021, 7</i>	E I	
① J7194	Factor ix, complex, per i.u. <i>Bebulin, Konyne 80, Profilnine SD, Proplex T</i>	K K2	② J7296	Levonorgestrel-releasing intrauterine contraceptive system, (Kyleena), 19.5 mg <i>Cross reference Q9984</i> <i>Kyleena</i> <i>Medicare Statute 1862(a)(1)</i>	♀ E I	
① J7195	Injection, factor ix (antihemophilic factor, recombinant) per iu, not otherwise specified <i>Aprolix, BeneFix, Idelvion, IXINITY</i>	K K2	② J7297	Levonorgestrel-releasing intrauterine contraceptive system (Liletta), 52 mg <i>Liletta</i> <i>Medicare Statute 1862(a)(1)</i> <i>AHA: 1Q 2016, 8</i>	♀ E I	
④ J7196	Injection, antithrombin recombinant, 50 i.u. <i>ATryn</i> <i>AHA: 1Q 2011, 6</i>	E 2 K 5	② J7298	Levonorgestrel-releasing intrauterine contraceptive system (Mirena), 52 mg <i>Mirena</i> <i>Medicare Statute 1862(a)(1)</i> <i>AHA: 1Q 2016, 8</i>	♀ E I	
① J7197	Antithrombin iii (human), per i.u. <i>Thrombate III</i>	K K2	② J7300	Intrauterine copper contraceptive <i>ParaGard, ParaGard T380A</i> <i>Medicare Statute 1862A1</i>	E I	
① J7198	Anti-inhibitor, per i.u. <i>Autoplex T, FEIBA</i> <i>NCD 110.3</i>	K K2	② J7301	Levonorgestrel-releasing intrauterine contraceptive system (Skyla), 13.5 mg <i>Skyla</i> <i>Medicare Statute 1862(a)(1)</i>	♀ E I	
① J7199	Hemophilia clotting factor, not otherwise classified <i>NCD 110.3</i>	B	② J7304	Contraceptive supply, hormone containing patch, each <i>Medicare Statute 1862.1</i>	E I	
① J7200	Injection, factor ix, (antihemophilic factor, recombinant), rixubis, per iu <i>Rixubis</i>	K K2	② J7306	Levonorgestrel (contraceptive) implant system, including implants and supplies <i>Kyleena</i>	E I	
① J7201	Injection, factor ix, fc fusion protein, (recombinant), alprolix, 1 i.u. <i>Alprolix</i>	K K2	Insertion of implantable contraceptive capsules			
① J7202	Injection, factor ix, albumin fusion protein, (recombinant), idelvion, 1 i.u. <i>Idelvion</i> <i>AHA: 4Q 2016, 9</i>	K K2	 <p>Capsules are implanted on the inside of the upper arm</p> <p>Small incision is made</p> <p>Capsules are inserted using a trocar</p>			
① J7203	Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (Rebinyn), 1 iu <i>Rebinyn</i> <i>AHA: 1Q 2019, 8</i>	K K2	② J7307	Etonogestrel (contraceptive) implant system, including implant and supplies <i>Nexplanon</i>	E I	
④ J7204	Injection, factor viii, antihemophilic factor (recombinant), (Esperoct), glycopegylated-exei, per iu <i>Esperoct</i>	G K 2	② J7308	Aminolevulinic acid HCL for topical administration, 20%, single unit dosage form (354 mg) <i>Levulan Kerastick</i>	K K2	
① J7205	Injection, factor viii fc fusion protein (recombinant), per iu <i>Eloctate</i> <i>AHA: 1Q 2016, 6</i>	K K2	① J7309	Methyl aminolevulinate (MAL) for topical administration, 16.8%, 1 gram <i>Metvixia</i> <i>AHA: 1Q 2011, 6</i>	E 2 K 5	
① J7207	Injection, factor viii, (antihemophilic factor, recombinant), pegylated, 1 i.u. <i>Adynovate, Jivi</i>	K K2	② J7310	Ganciclovir, 4.5 mg, long-acting implant <i>Vitrasert</i>	E 2 K 5	
① J7208	Injection, factor viii, (antihemophilic factor, recombinant), pegylated-awcl, (Jivi), 1 i.u. <i>AHA: 3Q 2019, 5</i>	K K2	② J7311	Injection, fluocinolone acetonide, intravitreal implant (Retisert), 0.01 mg <i>Retisert</i>	K K2	
④ J7209	Injection, factor viii, (antihemophilic factor, recombinant), (Nuwig), 1 i.u. <i>Nuwig</i>	K K2	② J7312	Injection, dexamethasone, intravitreal implant, 0.1 mg	K K2	
④ J7210	Injection, factor viii, (antihemophilic factor, recombinant), (Afystyla), 1 i.u. <i>Afystyla</i>	K K2				
④ J7211	Injection, factor viii, (antihemophilic factor, recombinant), (Kovaltry), 1 i.u. <i>Kovaltry</i>	K K2				
④ J7212	Factor viiia (antihemophilic factor, recombinant)-jncw (sevenfact), 1 microgram <i>Sevenfact</i> <i>AHA: 1Q 2021, 6</i>	G K 2				
② J7294	Segesterone acetate and ethinyl estradiol 0.15mg, 0.013mg per 24 hours; yearly vaginal system, each <i>Medicare Statute 1862(a)(1)</i> <i>AHA: 4Q 2021, 7</i>	E I				